Biotechnology firm Moderna is celebrating after “tremendously exciting” preliminary results from late-stage trials of its Covid-19 vaccine, says Sarah Knapton in The Daily Telegraph. So far, only five people in the trial who received the jab have contracted the virus, compared with 90 who received a placebo, implying that it is nearly 95%-effective in preventing infection. That would make it “even more effective than either the Pfizer/BioNTech or Russian jab”. The trials suggest that it can even protect “the elderly and vulnerable who are most at risk”, with no one who has received the jab developing severe Covid-19 yet (compared with 11 from the placebo group).
Moderna’s success is “stunning”, says Robert Cyran on Breakingviews. Not only is it highly effective, but side effects are also “moderate”. More importantly, it can be stored in a conventional freezer for six months, and in a fridge up to 30 days, making it much easier to distribute than Pfizer’s vaccine, which must be “kept far colder, complicating distribution”. This is particularly good news for emerging markets, who not only lack expensive storage facilities, but will also benefit from the fact that richer countries have ordered far more doses than they need. The US alone ordered 600 million doses.
Vindication after a volatile year
This is “great news”, says Lex in the Financial Times. The data also brings “vindication for one of the sector’s most divisive companies”. After a “record-setting” initial public offering in December 2018, its shares spent much of 2019 trading below its opening price. However, the coronavirus pandemic has put its work on messenger-RNA, which prompts the body to make its own medicine, “back into focus”. Indeed, there are hopes that the Covid-19 jab may represent “proof of concept” for other Moderna treatments, including a personalised cancer vaccine. So, it’s no surprise that its shares have risen by 390% this year. Thanks to its latest success, Moderna should easily find enough money to develop its other vaccines, says Charley Grant in The Wall Street Journal. Its $40bn valuation means it can raise funds by selling shares and it also has $4bn in cash on the books. Selling even 500 million doses of vaccine at $200 each would translate into $10bn, which should come with “attractive profit margins” as Moderna’s decision not to seek a partner means that “it won’t have to share those profits”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
AstraZeneca should also be happy, says Nils Pratley in the Guardian. Moderna’s trial suggests that its own jab, developed in conjunction with Oxford University, will report similarly good news next month. What’s more, it stands to benefit from the fact that it “made a very good bet” when it invested in Moderna as long ago as 2013, back when it was a “three-year-old biotechnology tiddler”. As a result, its 7.6% stake, which cost just $380m, is now worth $2.9bn – a “very decent” return.
-
How inheritance tax trick is helping families save ‘six-figure sums’Happy to skip a generation to save thousands on inheritance tax? A deed of variation could be the estate planning tool you need.
-
Nationwide: House prices unexpectedly dropped in AugustHouse prices fell by 0.1% in August in a surprise drop, according to Nationwide, as “affordability remains stretched”
-
Are wealthy whisky enthusiasts leaving Britain?Collectables Wealthy whisky enthusiasts are heading to tax-friendly countries such as Dubai, where there is more disposable income to spend on collectable luxuries like rare whisky.
-
'The rise and fall of Kodak is a lesson for the tech giants'Opinion The long decline of Kodak – a once-dominant company – shows why no business is safe from disruption, says Matthew Lynn
-
8 of the best properties for sale with kitchen gardensThe best properties for sale with kitchen gardens – from a 17th-century timber-framed hall house in Norfolk, to an Arts & Crafts house in West Sussex designed by Charles Voysey with a garden by Gertrude Jekyll
-
Why investors can no longer trust traditional statistical indicatorsOpinion The statistical indicators and data investors have relied on for decades are no longer fit for purpose. It's time to move on, says Helen Thomas
-
Investors rediscover the virtue of value investing over growthGrowth investing, betting on rapidly expanding companies, has proved successful since 2008. But now the other main investment style seems to be coming back into fashion.
-
8 of the best properties for sale with shooting estatesThe best properties for sale with shooting estates – from an estate in a designated Dark Sky area in Ayrshire, Scotland, to a hunting estate in Tuscany with a wild boar, mouflon, deer and hare shoot
-
The most likely outcome of the AI boom is a big fallOpinion Like the dotcom boom of the late 1990s, AI is not paying off – despite huge investments being made in the hope of creating AI-based wealth
-
What we can learn from Britain’s "Dashing Dozen" stocksStocks that consistently outperform the market are clearly doing something right. What can we learn from the UK's top performers and which ones are still buys?
